EP 1556020 B1 20090225 - USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS
Title (en)
USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS
Title (de)
VERWENDUNG VON CGRP-ANTAGONISTEN-VERBINDUNGEN ZUR BEHANDLUNG VON PSORIASIS
Title (fr)
UTILISATION DE COMPOSES ANTAGONISTES DU CGRP POUR LE TRAITEMENT DU PSORIASIS
Publication
Application
Priority
- IS 0300023 W 20030812
- IS 6496 A 20020812
Abstract (en)
[origin: US2023181693A1] A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the prepsoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/166 (2006.01); A61K 31/517 (2006.01); A61K 31/727 (2006.01); A61K 38/22 (2006.01); A61K 38/48 (2006.01); A61P 17/06 (2006.01); G01N 33/50 (2006.01); G01N 33/74 (2006.01)
CPC (source: EP KR US)
A61K 9/0014 (2013.01 - US); A61K 9/107 (2013.01 - EP US); A61K 31/00 (2013.01 - EP US); A61K 31/166 (2013.01 - EP US); A61K 31/4184 (2013.01 - KR); A61K 31/506 (2013.01 - US); A61K 31/517 (2013.01 - EP US); A61K 31/727 (2013.01 - EP KR US); A61K 38/225 (2013.01 - EP US); A61K 38/23 (2013.01 - KR US); A61K 38/482 (2013.01 - EP US); A61K 47/44 (2013.01 - EP US); A61P 17/00 (2018.01 - EP); A61P 17/02 (2018.01 - US); A61P 17/06 (2018.01 - EP US); C07K 16/26 (2013.01 - US); G01N 33/5008 (2013.01 - EP US); G01N 33/502 (2013.01 - EP US); G01N 33/5044 (2013.01 - EP US); G01N 33/5088 (2013.01 - EP US); G01N 33/566 (2013.01 - US); G01N 33/74 (2013.01 - EP US); G01N 2333/5753 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated extension state (EPC)
AL LT LV MK
DOCDB simple family (publication)
WO 2004014351 A2 20040219; WO 2004014351 A3 20040617; AT E423553 T1 20090315; AU 2003260944 A1 20040225; AU 2003260944 B2 20090514; BR 0313388 A 20050705; CA 2495498 A1 20040219; CA 2495498 C 20140415; CN 1674919 A 20050928; DE 60326370 D1 20090409; DK 1556020 T3 20090622; EA 008744 B1 20070831; EA 200500306 A1 20050825; EP 1556020 A2 20050727; EP 1556020 B1 20090225; ES 2323170 T3 20090708; IL 166761 A0 20060115; IL 166761 A 20101230; IS 2902 B 20141015; IS 7741 A 20050314; JP 2006501216 A 20060112; KR 101070213 B1 20111006; KR 20050056198 A 20050614; MX PA05001649 A 20050527; NO 20051262 L 20050311; NZ 538615 A 20080328; PL 375536 A1 20051128; PT 1556020 E 20090529; RS 20050132 A 20071115; RS 52750 B 20130830; SI 1556020 T1 20090831; US 10668132 B2 20200602; US 11266718 B2 20220308; US 2011150890 A1 20110623; US 2014220030 A1 20140807; US 2017065681 A1 20170309; US 2020338168 A1 20201029; US 2023181693 A1 20230615; US 9585940 B2 20170307
DOCDB simple family (application)
IS 0300023 W 20030812; AT 03784467 T 20030812; AU 2003260944 A 20030812; BR 0313388 A 20030812; CA 2495498 A 20030812; CN 03819423 A 20030812; DE 60326370 T 20030812; DK 03784467 T 20030812; EA 200500306 A 20030812; EP 03784467 A 20030812; ES 03784467 T 20030812; IL 16676105 A 20050208; IS 7741 A 20050314; JP 2004527284 A 20030812; KR 20057002417 A 20030812; MX PA05001649 A 20030812; NO 20051262 A 20050311; NZ 53861503 A 20030812; PL 37553603 A 20030812; PT 03784467 T 20030812; SI 200331590 T 20030812; US 201113039075 A 20110302; US 201313969288 A 20130816; US 201615355723 A 20161118; US 202016888708 A 20200530; US 202217969971 A 20221020; YU P13205 A 20030812